Kamada (NASDAQ:KMDA) Share Price Passes Below 200 Day Moving Average of $5.64

Kamada Ltd. (NASDAQ:KMDA) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.64 and traded as low as $4.95. Kamada shares last traded at $5.00, with a volume of 1,101 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research report on Thursday, May 9th. StockNews.com started coverage on shares of Kamada in a report on Thursday. They set a “buy” rating for the company.

Kamada Stock Performance

The stock has a market cap of $287.40 million, a P/E ratio of 21.74 and a beta of 1.06. The stock’s fifty day simple moving average is $5.27 and its 200-day simple moving average is $5.64.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The business had revenue of $37.74 million during the quarter, compared to the consensus estimate of $38.01 million. Kamada had a net margin of 8.33% and a return on equity of 5.50%. As a group, equities research analysts forecast that Kamada Ltd. will post 0.26 earnings per share for the current year.

Hedge Funds Weigh In On Kamada

Hedge funds and other institutional investors have recently made changes to their positions in the company. EWA LLC acquired a new position in shares of Kamada in the 4th quarter valued at approximately $68,000. Calton & Associates Inc. acquired a new position in Kamada during the 4th quarter worth approximately $111,000. Y.D. More Investments Ltd increased its position in Kamada by 107.1% during the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 15,000 shares in the last quarter. Aristides Capital LLC increased its position in Kamada by 41.6% during the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 16,635 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.